FDA Orange Book · active-ingredient family
Netarsudil mesylate
Netarsudil mesylate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:RHOPRESSA · NDA 208254
1
Brand (NDA)
0
Generics (ANDA)
15
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution/drops
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| RHOPRESSARLD | ALCON LABS INC | NDA 208254 | — | Dec 18, 2017 |
Listed patents (15)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8450344 | Jul 11, 2026 | in 22 d | SubstanceProductU-1524 |
| 9096569 | Jul 11, 2026 | in 22 d | SubstanceProductU-1524 |
| 10882840 | Jul 11, 2026 | in 22 d | U-1524 |
| 10532993 | Jul 11, 2026 | in 22 d | U-1524 |
| 11021456 | Jul 11, 2026 | in 22 d | U-1524 |
| 10174017 | Jan 27, 2030 | in 3 yr 8 mo | SubstanceProductU-1524 |
| 11618748 | Jan 27, 2030 | in 3 yr 8 mo | U-1524 |
| 10654844 | Jan 27, 2030 | in 3 yr 8 mo | SubstanceProductU-1524 |
| 11028081 | Jan 27, 2030 | in 3 yr 8 mo | U-1524 |
| 8394826 | Nov 10, 2030 | in 4 yr 6 mo | SubstanceProductU-1524 |
| 9931336 | Mar 14, 2034 | in 7 yr 10 mo | SubstanceProductU-1524 |
| 11020385 | Mar 14, 2034 | in 7 yr 10 mo | U-1524 |
| 10588901 | Mar 14, 2034 | in 7 yr 10 mo | SubstanceProductU-1524 |
| 9415043 | Mar 14, 2034 | in 7 yr 10 mo | Substance |
| 11185538 | Mar 14, 2034 | in 7 yr 10 mo | Product |
Netarsudil mesylate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
